Abstract
Haemophilus influenzae type b (Hib) was the leading cause of bacterial meningitis and a major cause of other serious invasive diseases among children aged <5 years in the United States before Hib conjugate vaccines became available in 1988. In 1991, all infants starting at age 2 months were recommended to receive Hib conjugate vaccines; by 1996, incidence of Hib invasive disease (i.e., illness clinically compatible with invasive disease, such as meningitis or sepsis, with isolation of the bacterium from a normally sterile site) among children aged <5 years had declined by >99%. This report presents 1998-2000 Haemophilus influenzae (Hi) surveillance data, which indicate that the incidence of reported Hib invasive disease remains low. Achieving the national health objective for 2010 of reducing to zero indigenous Hib invasive disease cases in children aged <5 years will require improved age-appropriate vaccination of children, complete reporting of vaccination and relevant medical histories, standardization of the serotyping procedure, and complete ascertainment and reporting of serotype for all Hi invasive disease cases.
Citations
Jan 9, 2003·Journal of Clinical Microbiology·Leslye L LaClaireUNKNOWN Active Bacterial Core Surveillance Team Members
Apr 19, 2003·Journal of Clinical Microbiology·Emma MeatsBrian G Spratt
Jul 5, 2003·Journal of Clinical Microbiology·Joshua M O'NeillGordon E Schutze
Jun 22, 2005·BMC Public Health·Michael J Cannon, Katherine Finn Davis
Aug 6, 2005·Journal of Clinical Microbiology·Claudio T SacchiLeonard W Mayer
Mar 14, 2007·Infection and Immunity·Zhigang JinRachel Schneerson
Apr 27, 2007·Journal of the Royal Society, Interface·Maia MartchevaRobert D Holt
Sep 1, 2007·BMC Infectious Diseases·Maria N TheodoridouChristos S Hadjichristodoulou
Jan 24, 2008·Infection and Immunity·Charles V RosadiniBrian J Akerley
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Michelle L Sill, Raymond S W Tsang
Feb 9, 2008·Emerging Infectious Diseases·Michael G BruceAlan J Parkinson
Jul 5, 2008·Emerging Infectious Diseases·Mehmet CeyhanSteve Gray
Feb 7, 2009·BMC Infectious Diseases·Paolo Giorgi RossiPiero Borgia
Mar 18, 2009·Infection and Immunity·Jane C HarringtonBrian J Akerley
Apr 22, 2009·BMC Infectious Diseases·Helen KaliesRüdiger von Kries
Jul 31, 2009·PloS One·Maria KaranikaChristos S Hadjichristodoulou
Oct 12, 2010·The Journal of Infectious Diseases·Josilene B T LimaJoice N Reis
Mar 2, 2011·Infection and Immunity·Sandy M S WongBrian J Akerley
Jul 2, 2011·PloS One·Ulla K GriffithsKaren Edmond
Oct 3, 2012·PloS One·Saleh M AlbarrakGuy H Palmer
Jan 24, 2008·Pediatric Emergency Care·Derek S WheelerJohn S Giuliano
Mar 1, 2012·Journal of Epidemiology and Global Health·Atef ShiblUNKNOWN Meningococcal Leadership Forum (“MLF”) Expert Group
Sep 11, 2007·Vaccine·Isabelle A RossiJames Watt
May 13, 2003·Expert Opinion on Pharmacotherapy·Nicola Principi, Susanna Esposito
Aug 30, 2006·Scandinavian Journal of Infectious Diseases·Irena NarkeviciuteRimantas Eidukevicius
Oct 10, 2007·FEMS Immunology and Medical Microbiology·Michelle L SillRaymond S W Tsang
Dec 24, 2010·Clinical and Vaccine Immunology : CVI·Nadine G RouphaelSandra Romero-Steiner
Jul 22, 2018·BMJ Open·Yuta SakanishiShunichi Fukuhara